TENAYA THERAPEUTICS INC (TNYA) Stock News
NASDAQ:TNYA - Nasdaq - US87990A1060 - Common Stock - Currency: USD
TNYA Latest News, Press Relases and Analysis
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., May 15, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a...
Tenaya Therapeutics to Highlight Capsid Engineering, Gene Editing and Manufacturing Research at the ASGCT 28th Annual Meeting
Advancements Lay the Groundwork for Future Genetic Medicines for Rare and Prevalent Forms of Heart Disease...
Tenaya Therapeutics Presents Interim Data from RIDGE™ Natural History and Seroprevalence Study of Adults with PKP2-associated ARVC at Heart Rhythm 2025
RIDGE is Largest Natural History Study Conducted with More Than 175 Participants Enrolled to Date with Arrhythmogenic Right Ventricular Cardiomyopathy Due...
Tenaya Therapeutics Announces Late Breaker Presentation of New Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 at American College of Cardiology Annual Meeting
TN-201 Has Been Well Tolerated at 3E13 vg/kg Dose New Biopsy Data Reaffirm Robust Transduction and RNA Expression with TN-201; RNA and Protein Levels...
Is Tenaya Therapeutics, Inc. (TNYA) the Cheapest Stock Insiders Are Buying In March?
We recently published a list of 15 Cheapest Stocks Insiders Are Buying In March. In this article, we are going to take a look at where Tenaya Therapeutics, Inc. (NASDAQ:TNYA) stands against other cheapest stocks insiders are buying in March. After solid gains Monday, the broader market index and blue chip companies traded flat Tuesday, […]
TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q2 2024
TNYA stock results show that Tenaya Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Top 3 Insider Stock Buys in March—Are They Still Good in April?
Insider buying of stocks like Matador Resources, Tenaya Therapeutics, and FirstSun picked up in March and points to value for investors.
Tenaya Therapeutics Publishes Preclinical Data Demonstrating TN-201 Enhances Cardiac Function and Survival in MYBPC3 Cardiomyopathy Models
Robust Evidence of Disease Reversal in Severe Knock Out Mice Model Supports Tenaya’s Clinical Development Plan to Evaluate TN-201 as a Potential Treatment...
Tenaya Therapeutics Announces Late Breaker and New Data Presentations at the American College of Cardiology’s Annual Scientific Session
Late Breaker Oral Presentation to Include New Data from Cohort 1 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201...
Mineralys, Tenaya, SpringWorks, COSCIENS, Metagenomi: 5 Biotech Stocks That Led Retail Follower Growth Last Week
Positive data from clinical trials, earnings readouts, M&A speculation and new research drew heavy interest from retail traders on Stocktwits for these tickers for the week ended March 14, 2025.
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy ...
TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Tenaya Therapeutics (NASDAQ:TNYA) just reported results for the first quarter o...
TNYA Stock Earnings: Tenaya Therapeutics Beats EPS for Q1 2024
TNYA stock results show that Tenaya Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
US Futures Tumble As Traders Await Trump's Congress Address: 'Volatility Is Certainly Being Fed By Trump 2.0 Moves,' Says Expert
U.S. stock futures declined on Tuesday following the worst trading day of 2025 on Monday. Futures fell in premarket trading except Nasdaq 100.
Tenaya Therapeutics Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...
Tenaya Therapeutics Announces Proposed Public Offering
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a...
Tenaya Therapeutics to Participate in Upcoming March Investor Conferences
SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a...
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
Continued Focus on Driving Advancement of TN-201 and TN-401 Gene Therapies for Cardiomyopathies Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2...
Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting in Increasing RNA...
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
Company to host conference call on Tuesday, December 17, at 8:00 a.m. ET...
Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
TN-401 AAV9-based Gene Therapy Designed to Deliver Fully Functional PKP2 Gene with the Aim of Increasing Protein Levels to Address Underlying Disease ...
Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Inclusion Criteria in the MyPEAKTM-1 Phase 1b/2 Trial of TN-201 Gene Therapy ...
Tenaya Therapeutics Announces Updates on TN-201 Gene Therapy Program for MYBPC3-associated HCM
Independent Data Safety and Monitoring Board Endorsed Dose Escalation and Broadening of Eligibility Criteria; Cohort 2 Now Enrolling Initial Data...
Tenaya Therapeutics to Participate in Upcoming Investment Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a...
Tenaya Therapeutics Announces Research Leadership Updates
Kathy Ivey, Ph.D., Promoted to Senior Vice President, Research and Timothy Hoey, Ph.D., Transitions to Advisory Role Pediatric Cardiologist and Genetic...
Tenaya Therapeutics to Participate at the TD Cowen Genetic Medicines & RNA Summit
SOUTH SAN FRANCISCO, Calif., June 18, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a...
Tenaya Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
Initial Data from Ongoing MyPEAK™-1 Phase 1b of TN-201 Expected in Second Half of 2024 Clinical Sites Activated for RIDGE™-1 Phase 1b Clinical Trial of...
Cytokinetics Reveals More From The Study That Boosted Shares 83% In A Day
The company is hoping to take on Bristol Myers Squibb's Camzyos, a treatment for obstructive HCM.
Tenaya Therapeutics to Highlight Growing Capabilities in Capsid Engineering, Gene Editing and Manufacturing at the American Society of Gene and Cell Therapy 27th Annual Meeting
Abstracts Demonstrate Tenaya’s Continued Innovation Across Core Competencies Facilitating Current Pipeline and Enabling Next Wave of Precision Heart...